Genmab — Marts 2016
-
Det kan da aldrig være negativt for aktien, at der kommer vigtige positive data
-
Taget fra EI:
Fra blogbuster: Following the interim analysis, the independent data monitoring committee (IDMC) has recommended to stop the Phase III Castor study early because Darzalex in combo with Velcade and Dex met the primary endpoint of improving PFS. This is outstanding news and highly significant. Janssen is now able to quickly file for label extension in 2nd line MM treatment, literally 1-2 years ahead of schedule. -
Det er vel ikke "1-2 years ahead of schedule"?
-
Ellers er jeg enig.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
